Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice

    June 2022 in “ Frontiers in immunology
    Eun-Jin Lee, Mingyu Kim, You Jeong Lee
    Image of study
    TLDR Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.
    The study explored the potential of using expanded regulatory T cells (Tregs) to treat alopecia areata (AA), an autoimmune disease where cytotoxic T lymphocytes attack hair follicles. Using the C3H/HeJ mouse model, researchers found that while Tregs can proliferate in the skin with the help of IL-2 cytokine antibody complex, their expansion was not enough to induce hair growth or suppress the autoreactive CD8 T cells responsible for AA. Consequently, the study concluded that simply increasing Treg numbers in the skin does not reverse established AA, indicating that a more comprehensive immunotherapy approach is necessary for effective treatment.
    Discuss this study in the Community →

    Research cited in this study

    12 / 12 results

    Related Community Posts Join

    6 / 1000+ results
      Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

      community Compressed part of research of theory of androgenic/anabolitic balance. AGA h-responders analytic. Theory of physio-metabolitic method of anti AGA treatment

      in Research  862 upvotes 3 months ago
      The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 2 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

      community Binding affinity of pyrilutamide!

      in Update  172 upvotes 2 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

      community Why I deleted my YouTube channel Part I

      in Update  118 upvotes 3 years ago
      A YouTuber named Kevin, also known as Rider_Of_Roach, who deleted his YouTube channel due to personal attacks and controversy surrounding his views on hair loss treatments. He advocated for FDA-approved treatments like finasteride and minoxidil but faced backlash from those who disagreed with him. The conversation also discusses his past trolling behavior and a lawsuit he filed against a website that published false information about him. Despite some disagreements, many viewers appreciated his research-based content and hope to see him return in the future.

    Related Research

    1 / 1 results